Table 1.

Drugs with available pharmacogenetic tests

Drug name	Pharmacogenetic test	Test namea	Pharmacogenetic information in drug label (drug label URLb)
Abacavir	HLA-B*5701	HLA-B5701 test	“Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction.” (Ziagen (abacavir) label: http://www.fda.gov/cder/foi/label/2008/020977s019,020978s022lbl.pdf)
5-FU	DPYD	TheraGuide 5-FU	“Efudex should not be used in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.” (Efudex (fluorouracil) label: http://www.fda.gov/cder/foi/label/2005/016831s049lbl.pdf)
Irinotecan	UGT1A1*28	Invader UGT1A1 Molecular Assay	“When administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of CAMPOSTAR should be considered for patients known to be homozygous for the UGT1A1*28 allele.” (Camptosar (irinotecan) label: http://www.fda.gov/cder/foi/label/2006/020571s030lbl.pdf)
Azathioprine 6-Mercaptopurine	TPMT	Prometheus TPMT Genetics	“It is recommended that consideration be given to either genotype or phenotype patients for TPMT.”(Imuran (azathioprine) label: http://www.fda.gov/cder/foi/label/2008/016324s031,017391s014lbl.pdf)
Warfarin	CYP2C9 VKORC1	Cytochrome P450 2C9 and VKORC1 warfarin genotyping	“The lower initiation doses should be considered for patients with certain genetic variations in CYP2C9 andVKORC1 enzymes.” (Coumadin (warfarin) label: http://www.fda.gov/cder/foi/label/2007/009218s105lblv2.pdf)
Tamoxifen	CYP2D6	Tamoxifen response	No information on CYP2D6 genotype and response to tamoxifen on drug label. (Tamoxifen label: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4262)
Carbamazepine Phenytoin	HLA-B*1502	HLA B*1502 carbamazepine sensitivity	“Patients with ancestry in genetically at-risk populations should be screened for the presence of HLA-B*1502 prior to initiating treatment with Tegretol. Patients testing positive for the allele should not be treated with Tegretol unless the benefit clearly outweighs the risk.” (Tegretol (carbamazepine) label: http://www.fda.gov/cder/foi/label/2007/016608s098lbl.pdf)
Clozapine	HLA-DQB1	Clozapine	No information on HLA-DQB1 genotype and response to clozapine on drug label. (Clozaril (clozapine) label: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8631)
Trastuzumab	HER2	PathVysion HER2 DNA Probe Kit	“Detection of HER2 protein overexpression is necessary for selection of patients appropriate for Herceptin therapy because these are the only patients studied for whom benefit has been shown. Assessment for HER2 overexpression and of HER2 gene amplification should be performed by laboratories with demonstrated proficiency in the specific technology being utilized.” (Herceptin (trastuzumab) label: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8221)
Dasatinib Imatinib	BCR-ABL (BCR and ABL1 translocation)	BCR-ABL quantitation in CML; BCR-ABL mutations in CML	“SPRYCEL is also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” (Sprycel (dasatinib) label: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8592)
Tetrabenazine	CYP2D6	AmpliChipCYP450Test	“Patients should be genotyped for CYP2D6 prior to treatment with daily doses of tetrabenazine over 50 mg. Patients who are poor metabolizers should not be given daily doses greater than 50 mg.” (Xenazine (tetrabenazine) label: http://www.fda.gov/cder/foi/label/2008/021894lbl.pdf)

5-FU, 5-fluorouracil; CML, chronic myelogenous leukemia; HER2, human epidermal growth factor receptor 2;TPMT, thiopurine methyltransferase.

^aThe names of specific pharmacogenetic tests are provided for information purposes only as examples of available tests and do not constitute an endorsement of any particular test or vendor.

^bAll URLs were retrieved on 3 March 2009. Pharmacogenetic tests and vendors of these tests were identified through Internet searches using the Google search engine (http://www.google.com) and by searching the Food and Drug Administration (FDA) website (http://www.fda.gov) and the Pharmacogenomics Reporter website (http://www.genomeweb.com/newsletter/pharmacogenomics-reporter) using gene names, variant names, and/or drug names as query terms. For each drug, the most recent drug label was retrieved from the FDA website (http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm); if the most recent drug label version was unavailable from the FDA but was available at DailyMed, the label was retrieved from DailyMed (http://dailymed.nlm.nih.gov/dailymed/about.cfm).